Adjuvant cemiplimab prolonged DFS compared with placebo for certain patients with cutaneous squamous cell carcinoma, ...

The Food and Drug Administration has approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma.

in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial met its primary endpoint, demonstrating a 68% reduction in the risk of disease recurrence or death ...

in patients with high-risk cutaneous squamous cell carcinoma (CSCC) following surgery. The trial met its primary endpoint, demonstrating a 68% reduction in the risk of disease recurrence or death when ...

Pharmaceuticals announced positive results from the Phase 3 C-POST trial, which demonstrated that adjuvant treatment with PD-1 ...